论文部分内容阅读
目的探讨阿奇霉素序贯治疗支原体肺炎(MP)的临床疗效可行性及安全性。方法经血清学检测肺炎衣原体抗体阳性的肺炎126例,随机分为两组各63例,治疗组采用阿奇霉素治疗,对照组用红霉素治疗,观察治疗前后患者症状,肺部体征的变化及不良反应。结果治疗组、对照组总有效率分别为95.2%和79.4%,两组比较差异具有统计学意义,不良反应的差异有统计学意义,治疗组明显优于对照组。结论阿奇霉素治疗支原体肺炎使用安全、简便,疗效好,值得临床推广使用。
Objective To investigate the feasibility and safety of azithromycin sequential therapy for mycoplasma pneumonia (MP). Methods Serological detection of Chlamydia pneumoniae-positive pneumonia in 126 cases were randomly divided into two groups of 63 cases, the treatment group treated with azithromycin, the control group treated with erythromycin, observed before and after treatment in patients with symptoms, changes in lung signs and poor reaction. Results The total effective rates of the treatment group and the control group were 95.2% and 79.4% respectively. The difference between the two groups was statistically significant. The difference in adverse reactions was statistically significant. The treatment group was significantly better than the control group. Conclusion Azithromycin safe, simple and effective in the treatment of Mycoplasma pneumonia is worthy of clinical promotion.